antibody_research

The 15th World Bispecifics Summit in Boston showcased breakthroughs. Biointron shares highlights shaping the future of bispecific antibody therapeutics.

Phage display technology revolutionizes antibody discovery. Biointron applies this platform to identify high-affinity binders and accelerate therapeutic innovation.

The 12th Immuno-Oncology Summit in Philadelphia spotlighted antibody therapeutics. Biointron shares event highlights driving progress in cancer immunotherapy.

BIX 2024 in Seoul spotlighted biotech and antibody advances. Biointron reports event highlights shaping innovation across discovery, development, and therapeutics.

PEGS Boston 2024 spotlighted protein and antibody engineering advances. Biointron reports event highlights that define the next era of therapeutic innovation.

The 4th Fc-Mediated Function Summit in Boston showcased Fc engineering advances. Biointron reports key insights driving next-generation antibody therapeutics.

AACR 2024 in San Diego spotlighted breakthroughs in cancer research. Biointron shares highlights on antibody therapeutics, discovery platforms, and translational science.

Biointron shares highlights from Biologics 2024 in London, UK—covering advances in antibody discovery, engineering, and partnerships shaping the future of biologics.

Biointron’s ISO 9001:2015-certified manufacturing standards ensure reliable, high-quality antibody production with rigorous QC processes and global CRO expertise.

Antibody labeling matters. Compare conjugation chemistries, optimize labeling degree, and master QC checks that ensure bright, specific, and reproducible results.

PepTalk 2024 delivered key insights into antibody development. Explore highlights on formulation, analytics, and modalities that shape the future of biotech innovation.

Beyond ELISA, discover multiplexed, label-free, and rapid immunoassays. Learn where they excel, how they are validated, and their role in modern diagnostics.

Monoclonal antibodies played a vital role in COVID-19. Learn how they neutralize variants, guide rapid therapeutic design, and expand strategies for pandemic preparedness.

How ELISA kits achieve specific, reliable readouts: key components, curve fitting, common pitfalls, and QC practices that keep results trustworthy across studies.

Compare delivery options for antibody‑based therapies—conjugates, nanoparticles, liposomes, and long‑acting platforms—to improve exposure, precision, and patient safety.